Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women

Kathleen C. Light, Alan L. Hinderliter, Sheila Grace West, Karen M. Grewen, John F. Steege, Andrew Sherwood, Susan S. Girdler

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: Postmenopausal estrogen replacement, with or without progestins, has been related to lower cardiovascular risks. Objective: We investigated whether the actions of estrogen on vascular resistance contribute to this cardioprotective effect. Design and methods: In a 6-month double-blind study, pre- and post-treatment blood pressure, cardiac index, total vascular resistance index and plasma catecholamine responses during baseline and mental stressors were compared in 69 women (including 19 with mild hypertension but no history of heart disease). Women were randomized to receive either conjugated estrogens alone, estrogens plus medroxyprogesterone, or placebo. Results: Both groups on active hormone replacement showed similar decreases in vascular resistance and modest blood pressure reductions, which differed from the unchanged responses of those on placebo (P < 0.05) after 3 and 6 months of treatment. Hypertensive women showed greater reductions in vascular resistance than normotensives (P < 0.05) and their blood pressure reductions tended to be larger. Women receiving hormone replacement showed increased stroke volume and cardiac index at 6 months, particularly among hypertensives and those receiving medroxyprogesterone (P < 0.05). Hormone replacement was also related to decreases in plasma norepinephrine. Finally, in 33 women receiving hormone replacement, significant 5 and 3% decreases in echocardiographic measures of left ventricular mass index and relative wall thickness were evident at 6 months (P < 0.05), while 20 placebo-treated women showed no reliable echocardiographic improvements (P = NS). Conclusions: These findings suggest that estrogen-mediated reductions in hemodynamic load on the heart may contribute to the reduced risk of cardiovascular events in relatively healthy postmenopausal women who use hormone replacement.

Original languageEnglish (US)
Pages (from-to)269-278
Number of pages10
JournalJournal of Hypertension
Volume19
Issue number2
DOIs
StatePublished - 2001

Fingerprint

Hemodynamics
Hormones
Vascular Resistance
Medroxyprogesterone
Estrogens
Placebos
Blood Pressure
Conjugated (USP) Estrogens
Estrogen Replacement Therapy
Progestins
Double-Blind Method
Stroke Volume
Catecholamines
Heart Diseases
Norepinephrine
Therapeutics
Hypertension

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology

Cite this

Light, Kathleen C. ; Hinderliter, Alan L. ; West, Sheila Grace ; Grewen, Karen M. ; Steege, John F. ; Sherwood, Andrew ; Girdler, Susan S. / Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. In: Journal of Hypertension. 2001 ; Vol. 19, No. 2. pp. 269-278.
@article{5e0805b255d14807b1d989cf1790d452,
title = "Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women",
abstract = "Background: Postmenopausal estrogen replacement, with or without progestins, has been related to lower cardiovascular risks. Objective: We investigated whether the actions of estrogen on vascular resistance contribute to this cardioprotective effect. Design and methods: In a 6-month double-blind study, pre- and post-treatment blood pressure, cardiac index, total vascular resistance index and plasma catecholamine responses during baseline and mental stressors were compared in 69 women (including 19 with mild hypertension but no history of heart disease). Women were randomized to receive either conjugated estrogens alone, estrogens plus medroxyprogesterone, or placebo. Results: Both groups on active hormone replacement showed similar decreases in vascular resistance and modest blood pressure reductions, which differed from the unchanged responses of those on placebo (P < 0.05) after 3 and 6 months of treatment. Hypertensive women showed greater reductions in vascular resistance than normotensives (P < 0.05) and their blood pressure reductions tended to be larger. Women receiving hormone replacement showed increased stroke volume and cardiac index at 6 months, particularly among hypertensives and those receiving medroxyprogesterone (P < 0.05). Hormone replacement was also related to decreases in plasma norepinephrine. Finally, in 33 women receiving hormone replacement, significant 5 and 3{\%} decreases in echocardiographic measures of left ventricular mass index and relative wall thickness were evident at 6 months (P < 0.05), while 20 placebo-treated women showed no reliable echocardiographic improvements (P = NS). Conclusions: These findings suggest that estrogen-mediated reductions in hemodynamic load on the heart may contribute to the reduced risk of cardiovascular events in relatively healthy postmenopausal women who use hormone replacement.",
author = "Light, {Kathleen C.} and Hinderliter, {Alan L.} and West, {Sheila Grace} and Grewen, {Karen M.} and Steege, {John F.} and Andrew Sherwood and Girdler, {Susan S.}",
year = "2001",
doi = "10.1097/00004872-200102000-00014",
language = "English (US)",
volume = "19",
pages = "269--278",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women. / Light, Kathleen C.; Hinderliter, Alan L.; West, Sheila Grace; Grewen, Karen M.; Steege, John F.; Sherwood, Andrew; Girdler, Susan S.

In: Journal of Hypertension, Vol. 19, No. 2, 2001, p. 269-278.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Hormone replacement improves hemodynamic profile and left ventricular geometry in hypertensive and normotensive postmenopausal women

AU - Light, Kathleen C.

AU - Hinderliter, Alan L.

AU - West, Sheila Grace

AU - Grewen, Karen M.

AU - Steege, John F.

AU - Sherwood, Andrew

AU - Girdler, Susan S.

PY - 2001

Y1 - 2001

N2 - Background: Postmenopausal estrogen replacement, with or without progestins, has been related to lower cardiovascular risks. Objective: We investigated whether the actions of estrogen on vascular resistance contribute to this cardioprotective effect. Design and methods: In a 6-month double-blind study, pre- and post-treatment blood pressure, cardiac index, total vascular resistance index and plasma catecholamine responses during baseline and mental stressors were compared in 69 women (including 19 with mild hypertension but no history of heart disease). Women were randomized to receive either conjugated estrogens alone, estrogens plus medroxyprogesterone, or placebo. Results: Both groups on active hormone replacement showed similar decreases in vascular resistance and modest blood pressure reductions, which differed from the unchanged responses of those on placebo (P < 0.05) after 3 and 6 months of treatment. Hypertensive women showed greater reductions in vascular resistance than normotensives (P < 0.05) and their blood pressure reductions tended to be larger. Women receiving hormone replacement showed increased stroke volume and cardiac index at 6 months, particularly among hypertensives and those receiving medroxyprogesterone (P < 0.05). Hormone replacement was also related to decreases in plasma norepinephrine. Finally, in 33 women receiving hormone replacement, significant 5 and 3% decreases in echocardiographic measures of left ventricular mass index and relative wall thickness were evident at 6 months (P < 0.05), while 20 placebo-treated women showed no reliable echocardiographic improvements (P = NS). Conclusions: These findings suggest that estrogen-mediated reductions in hemodynamic load on the heart may contribute to the reduced risk of cardiovascular events in relatively healthy postmenopausal women who use hormone replacement.

AB - Background: Postmenopausal estrogen replacement, with or without progestins, has been related to lower cardiovascular risks. Objective: We investigated whether the actions of estrogen on vascular resistance contribute to this cardioprotective effect. Design and methods: In a 6-month double-blind study, pre- and post-treatment blood pressure, cardiac index, total vascular resistance index and plasma catecholamine responses during baseline and mental stressors were compared in 69 women (including 19 with mild hypertension but no history of heart disease). Women were randomized to receive either conjugated estrogens alone, estrogens plus medroxyprogesterone, or placebo. Results: Both groups on active hormone replacement showed similar decreases in vascular resistance and modest blood pressure reductions, which differed from the unchanged responses of those on placebo (P < 0.05) after 3 and 6 months of treatment. Hypertensive women showed greater reductions in vascular resistance than normotensives (P < 0.05) and their blood pressure reductions tended to be larger. Women receiving hormone replacement showed increased stroke volume and cardiac index at 6 months, particularly among hypertensives and those receiving medroxyprogesterone (P < 0.05). Hormone replacement was also related to decreases in plasma norepinephrine. Finally, in 33 women receiving hormone replacement, significant 5 and 3% decreases in echocardiographic measures of left ventricular mass index and relative wall thickness were evident at 6 months (P < 0.05), while 20 placebo-treated women showed no reliable echocardiographic improvements (P = NS). Conclusions: These findings suggest that estrogen-mediated reductions in hemodynamic load on the heart may contribute to the reduced risk of cardiovascular events in relatively healthy postmenopausal women who use hormone replacement.

UR - http://www.scopus.com/inward/record.url?scp=0035143870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035143870&partnerID=8YFLogxK

U2 - 10.1097/00004872-200102000-00014

DO - 10.1097/00004872-200102000-00014

M3 - Article

VL - 19

SP - 269

EP - 278

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 2

ER -